- Home
- PACH vs XFOR Comparison
PACH vs XFOR Comparison
Compare PACH & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.27
Company Overview
Basic Information| Metric | PACH | XFOR |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.4M | 276.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PACH | XFOR |
|---|---|---|
| Price | $10.13 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 12.9K | ★ 475.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,263.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.94 | $0.17 |
| 52 Week High | $10.16 | $6.63 |
Technical Indicators
Market Signals| Indicator | PACH | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 42.95 |
| Support Level | $9.94 | $3.18 |
| Resistance Level | $10.16 | $3.77 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 100.00 | 44.44 |
Price Performance
Historical Comparison PACH
XFOR
About PACH Pioneer Acquisition I Corp Class A Ordinary Shares
Pioneer Acquisition I Corp is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.